MUSTARGEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mustargen, and what generic alternatives are available?
Mustargen is a drug marketed by Recordati Rare and is included in one NDA.
The generic ingredient in MUSTARGEN is mechlorethamine hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the mechlorethamine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MUSTARGEN?
- What are the global sales for MUSTARGEN?
- What is Average Wholesale Price for MUSTARGEN?
Summary for MUSTARGEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,810 |
| Drug Prices: | Drug price information for MUSTARGEN |
| DailyMed Link: | MUSTARGEN at DailyMed |
Recent Clinical Trials for MUSTARGEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Eastern Cooperative Oncology Group | Phase 3 |
| National Cancer Institute (NCI) | Phase 3 |
US Patents and Regulatory Information for MUSTARGEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare | MUSTARGEN | mechlorethamine hydrochloride | INJECTABLE;INJECTION | 006695-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
